 Highlights of This Issue 4171

SPECIAL FEATURES

CCR Translations

4173  
CHK It Out! Blocking WEE Kinase Routs TP53 
Mutant Cancer
Julie E. Bauman and Christine H. Chung
See related article, p. 4274

Statistics in Clinical Cancer Research

4176  
Historical Controls for Metastatic Pancreatic 
Cancer: Benchmarks for Planning and 
Analyzing Single-Arm Phase II Trials
Philip A. Philip, Kari Chansky, Michael LeBlanc, 
Lawrence Rubinstein, Lesley Seymour, S. Percy Ivy, 
Steven R. Alberts, Paul J. Catalano, and John Crowley

Molecular Pathways

4186  
Molecular Pathways: Targeting NRAS in 
Melanoma and Acute Myelogenous Leukemia
Douglas B. Johnson, Keiran S.M. Smalley, and 
Jeffrey A. Sosman

4193  
Molecular Pathways: The Basis for Rational 
Combination Using MEK Inhibitors in KRAS- 
Mutant Cancers
Shunsuke Okumura and Pasi A. Jänne

Perspectives

4200  
Toward a Drug Development Path That Targets 
Metastatic Progression in Osteosarcoma
Chand Khanna, Timothy M. Fan, Richard Gorlick, 
Lee J. Helman, Eugenie S. Kleinerman, 
Peter C. Adamson, Peter J. Houghton, 
William D. Tap, Danny R. Welch, Patricia S. Steeg, 
Glenn Merlino, Poul H.B. Sorensen, Paul Meltzer, 
David G. Kirsch, Katherine A. Janeway, 
Brenda Weigel, Lor Randall, Stephen J Withrow, 
Melissa Paoloni, Rosandra Kaplan, 
Beverly A. Teicher, Nita L. Selbel, Malcolm Smith, 
Aykut Uren, Shreyaskumar R. Patel, Jeffrey Trent, 
Sharon A. Savage, Lisa Mirabello, Denise Reinke, 
Donald A. Barkaukas, Mark Krailo, and 
Mark Bernstein

CANCER THERAPY: CLINICAL

4218  
Phase II Study of Single-Agent Orteronel 
(TAK-700) in Patients with Nonmetastatic 
Castration-Resistant Prostate Cancer and 
Rising Prostate-Specific Antigen
Maha Hussain, Paul G. Corn, M. Dror Michaelson, 
Hans J. Hammers, Joshi J. Alumkal, Charles J. Ryan, 
Justine Y. Bruce, Susan Moran, Shih-Yuan Lee, 
H. Mark Lin, and Daniel J. George for the Prostate 
Cancer Clinical Trials Consortium, a program of the 
Department of Defense Prostate Cancer Research 
Program and the Prostate Cancer Foundation

4228  
Treatment with Chemotherapy and Dendritic 
Cells Pulsed with Multiple Wilms’ Tumor 1 
(WT1)–Specific MHC Class I/II–Restricted 
Epitopes for Pancreatic Cancer
Shigéo Koido, Sadamu Homma, Masato Okamoto, 
Kazuki Takakura, Masako Mori, Shinji Yoshizaki, 
Shintaro Tsukinaga, Shinnich Odaehara, 
Seita Koyama, Hiroo Imazu, Kan Uchijama, 
Mikio Kajihara, Hiroshi Arakawa, Takeyuki Misawa, 
Yoichi Toyama, Satoru Yanagisawa, 
Masahiro Ikegami, Shin Kan, Kazumi Hayashi, 
Hideo Komita, Yuko Kamata, Masaki Ito, 
Takefumi Ishidao, Sei-ichi Yusa, 
Shigetaka Shimodaia, Jianlin Gong, 
Haruo Sugiyama, Toshifumi Okhusa, and Hisao Tajiri

4240  
Randomized Phase Ib/II Trial of Rilotumumab 
or Ganitumab with Panitumumab versus 
Panitumumab Alone in Patients with Wild- 
type KRAS Metastatic Colorectal Cancer
Eric Van Cutsem, Cathy Eng, Elzbieta Nowara, 
Anna Świeboda-Sadlej, Niall C. Tebbutt, 
Edith Mitchell, Irina Davidenko, Joe Stephenson, 
Elena Elez, Hans Prenen, Hongjie Deng, Rui Tang, 
Ian McCaffery, Kelly S. Oliner, Lisa Chen, 
Jennifer Gansert, Elwyn Loh, Dominic Smethurst, 
and Josep Taberner
A Novel KLF4/LDHA Signaling Pathway Regulates Aerobic Glycolysis in and Progression of Pancreatic Cancer
Min Shi, Jiujie Cui, Jiawei Du, Daoyan Wei, Zhiliang Jia, Jun Zhang, Zhenggang Zhu, Yong Gao, and Keping Xie

Preoperative GNAS and KRAS Testing in the Diagnosis of Pancreatic Mucinous Cysts

Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma

PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-cis Retinoic Acid–Mediated Differentiation in Neuroblastoma
Nilay Shah, Jianjun Wang, Julia Selich-Anderson, Garrett Graham, Hasan Siddiqui, Xin Li, Javed Khan, and Jeffrey Toretsky

Correction: interleukin-7 Mediates Selective Expansion of Tumor-Redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-Cell Inhibition

Correction: A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

Correction: Bim Polymorphisms: Influence on Function and Response to Treatment in Children with Acute Lymphoblastic Leukemia

ABOUT THE COVER
Integrative analysis of clear cell renal cell carcinoma shows predominant hypermethylation. A circos plot shows alterations in DNA methylation (hypermethylation in blue, outer ring), copy number variations (amplifications in red and deletions in green, middle ring), and expression (underexpressed in green, overexpressed in orange, innermost ring) in renal cell carcinoma when compared. For details, see the article by Hu and colleagues on page 4349 of this issue.